core cancer

core cancer

(jargon)
A process that exhibits a slow but inexorable resource leak - like a cancer, it kills by crowding out productive "tissue".
References in periodicals archive ?
As of 2018, Aflac committed to its US workforce and increase in its 401(k) match to 100% on the first 4% of employee contribution, while making a one-time contribution of USD500 to every employee's 401(k) plan; and offer certain hospital and accident insurance products to all free of charge, as it currently does with its core cancer insurance product.
Over the past 40 years the medical and scientific communities have progressively acknowledged the importance and benefits of managing cancer symptoms and the secondary effects of cancer treatment alongside the provision of core cancer therapies.
It was reported on Friday that the contract has been signed to explore next-generation strategies for the company's core cancer technology.
Such a move would allow Roche to enter the area of rare or so-called orphan diseases and diversify beyond its core cancer competencies, Reuters said.
Foundation Medicine's core cancer diagnostics capability is a comprehensive cancer genomic test that provides physicians with genomic information that may help match patients with treatments or clinical trials specific for the genomic profile of their tumor.
The stunning brunette had just bought a shirt he had donated to the Anema E Core Cancer Research dinner.
Learners will demonstrate an understanding of how social environments affect health through the application of core cancer concepts in real-life simulations (NHES 1.
Foundation Medicine's industry and academic partnerships complement the company's core cancer diagnostics capability, a comprehensive cancer genomic test that provides physicians with genomic information that may help match patients with treatments or clinical trials specific for the genomic profile of their tumor.
These partnerships complement Foundation Medicine's core cancer diagnostics capability, a comprehensive cancer genomic test that provides physicians with genomic information that may help match patients with treatments or clinical trials specific for the genomic profile of their tumor.
Our focus remains on our core cancer assets and we expect to achieve several key upcoming milestones for these programs, including Genentech's initiation of Phase II testing of our Hedgehog systemic antagonist in one or more solid tumor indications in 2008 and a near-term IND application for our proprietary targeted cancer drug candidate CUDC-101, a potentially first-in-class small molecule inhibitor of EGFR, Her2 and HDAC.
We are making progress toward our goals of reorganizing the company around our core cancer detection technology and leveraging our ISF testing technology," said Mark L.
Isaacs stated, "I look forward to working with my new colleagues and establishing collaborative partnerships to enable Oncologic to achieve its full potential in both its core cancer technology and other strategic areas.